Jane is currently Executive Chair of Talee Bio, a gene therapy company focused on cystic fibrosis as well as diseases of the lung and Managing Partner of Militia Hill Ventures. Jane is co-founder and former CEO of NuPathe Inc. (NASDAQ: PATH), a biopharmaceutical company focused on diseases of the central nervous system which was sold to Teva in 2014. She also co-founded and served as Executive Vice President of Auxilium Pharmaceuticals (NASDAQ: AUXL), a biopharmaceutical company focused on urology which was sold to Endo Pharmaceuticals in 2015. Prior to launching and leading these two successful biopharmaceutical companies, Jane was VP, Secretary & General Counsel of IBAH, Inc. (NASDAQ: IBAH), a multinational clinical research organization.
diseases of the central nervous system